Nasatapp

Each tablet contains phenylpropanolamine HCl 15 mg and brompheniramine maleate 12 mg.
Each 5 mL (1 tsp) syrup contains phenylpropanolamine HCl 12.5 mg and brompheniramine maleate 4 mg.
Each mL of syrup for oral drops contains phenylpropanolamine HCl 6.25 mg and brompheniramine maleate 2 mg.
Nasatapp is a combination of the decongestant, phenylpropanolamine HCl, and the antihistamine, brompheniramine maleate. This combination reduces excessive nasopharyngeal secretion and diminishes inflammatory mucosal edema and congestion in the upper respiratory tract. The antihistamine action of brompheniramine maleate reduces or diminishes the allergic response of nasal tissues. It is complemented by the mild vasoconstrictor action of phenylpropanolamine HCl, which provides a nasal decongestant effect.

Indicated for allergic and vasomotor or other hyperactive nasal disorders and acute coryza, relief of nasal congestion and hypersecretion. Relief of nasal congestion in infants up to children 12 years of age.

Tablet: 1 tablet twice a day.
Syrup: Adult: 1-2 tsp (5-10 mL) to be given every 6-8 hrs.
Children 5-12 years: 1 tsp (5 mL); 3-4 years: ¾ tsp (3.75 mL); 7 months to 2 years: ½ tsp (2.5 mL); 1-6 months: ¼ tsp (1.25 mL).
Drops: Infants 7 months to 2 years: 1 mL; Up to 6 months: 0.5 mL.

Brompheniramine is contraindicated in patients with known brain damage or epilepsy.

Care is necessary if phenylpropanolamine (PPA) is to be given to patients with high blood pressure, toxic goiter, benign prostatic hypertrophy, heart rate irregularity, glaucoma and to those receiving antidepressant therapy. Patients with heart disease and uncontrolled or untreated high blood pressure should consult a doctor prior to taking PPA.
Tablet: Nasatapp tablet contains tartrazine (FD&C yellow No. 5) which may cause allergic reaction including bronchial asthma in certain susceptible person.

Phenylpropanolamine HCl: Sympathomimetic agents should be used with caution in patients which may be particularly susceptible to their effects, particularly those with hyperthyroidism. Great care is also needed in patients with cardiovascular disease eg, ischemic heart disease, arrhythmia or tachycardia, occlusive vascular disorders eg, arteriosclerosis, hypertension or aneurysms. Anginal pain may be precipitated in patients with angina pectoris.
Excessive administration of sympathomimetic agents to the nasal mucosa may produce rebound congestion and rhinorrhea. Care is also required when sympathomimetic agents are given to patients with diabetes mellitus or closed-angle glaucoma.
Brompheniramine Maleate: Antihistamine should not be given to premature infants or neonates. This group of patients has an increased susceptibility to antimuscarinic effects. Elderly patients are also more susceptible to many adverse effects of antihistamines including antimuscarinic effects, sedation and hypotension.
Because of their antimuscarinic properties, antihistamines should be used with care in conditions eg, closed-angle glaucoma, urinary retention, prostatic hypertrophy, or pyloroduodenal obstruction.
Effects on the Ability to Drive or Operate Machinery: Brompheniramine Maleate: Many antihistamines may cause drowsiness, so patients affected should not drive or operate machinery. Patients should avoid alcoholic drink.

Severe hypertension, drowsiness, lassitude, nausea, giddiness, dry mouth, mydriasis, increased irritability and excitement.

Actions prolonged by monoamine oxidase inhibitors (MAOIs). Potentiate effects of other CNS depressants.

Store at temperatures not exceeding 30°C.

Cough & Cold Preparations

R01BA51 - phenylpropanolamine, combinations ; Belongs to the class of systemic sympathomimetic preparations used as nasal decongestants.

Rx